Cite
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
MLA
Bhave, Manali A., et al. “Comprehensive Genomic Profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) Metastatic Breast Cancer: Prevalence along Treatment Course and Predictive Value for Endocrine Therapy Resistance in Real-World Practice.” Breast Cancer Research & Treatment, vol. 207, no. 3, Oct. 2024, pp. 599–609. EBSCOhost, https://doi.org/10.1007/s10549-024-07376-w.
APA
Bhave, M. A., Quintanilha, J. C. F., Tukachinsky, H., Li, G., Scott, T., Ross, J. S., Pasquina, L., Huang, R. S. P., McArthur, H., Levy, M. A., Graf, R. P., & Kalinsky, K. (2024). Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Research & Treatment, 207(3), 599–609. https://doi.org/10.1007/s10549-024-07376-w
Chicago
Bhave, Manali A., Julia C. F. Quintanilha, Hanna Tukachinsky, Gerald Li, Takara Scott, Jeffrey S. Ross, Lincoln Pasquina, et al. 2024. “Comprehensive Genomic Profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) Metastatic Breast Cancer: Prevalence along Treatment Course and Predictive Value for Endocrine Therapy Resistance in Real-World Practice.” Breast Cancer Research & Treatment 207 (3): 599–609. doi:10.1007/s10549-024-07376-w.